In addition, evidence has been reported on the efficacy of SHP009 to inhibit the mutant E76A SHP2, the form frequently identified in Noonan syndrome and leukemia, for which an IC50 of 0.12 μM has been measured [138]. This evidence concerns the gene PTPN11 and Noonan syndrome.